What if local anesthesia didn’t wear off after surgery? Or at least not for three or four days. That’s a concept Heron Therapeutics is moving into Phase 3 trials this year, with its long-acting and potentially opioid-sparing formulation.
Based in San Diego, California, Heron’s journey started back in the 1990s with a chemistry company called Advanced Polymer Sciences.
